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Abstract
Background: To target optimised medical care the Danish guidelines for diabetes recommend stratification of
patients with type 2 diabetes (T2D) into three levels according to risk and complexity of treatment. The aim was to
describe the T2D population in an outpatient clinic, measure the compliance of the endocrinologists’ to perform
risk stratification, and investigate the level of concordance between stratification performed by the endocrinologists
and objective assessments.
Methods: A cross-sectional study with data collected from medical records and laboratory databases. The Danish
risk stratification model contained the following criteria: HbA1c, blood pressure, metabolic complications,
microvascular and macrovascular complications. Stratification levels encompassed: level 1 (uncomplicated), level 2
(intermediate risk) and level 3 (high risk). Objective assessments were conducted independently by two health
professionals, and compared with the endocrinologists’ assessments. In order to test the degree of concordance,
we conducted Cohen's kappa, McNemar’s test for marginal homogeneity, and Bowker’s test for symmetry.
Results: Of 245 newly referred patients, 209 (85 %) were stratified by the endocrinologists to level 1 (16 %), level 2
(55 %) and level 3 (29 %). By objective assessments, 4 % were stratified to level 1, 51 % to level 2 and 45 % to level
3. Of 419 long-term follow-up patients, 380 (91 %) were stratified by the endocrinologists to level 1 (5 %), level 2
(57 %), level 3 (38 %). By objective assessments, 3 % were stratified to level 1, 58 % to level 2 and 39 % to level 3.
The concordance rate between endocrinologists’ and objective assessments was 63 % among newly referred
(kappa 0.39; fair agreement) and 67 % for long-term follow-up (kappa 0.45; moderate agreement). Among newly
referred patients, the endocrinologists stratified less patients at level 3 compared to objective assessments (p < 0.0001).
There were no significant differences in marginal distribution within long-term follow-up patients.
Conclusion: Type 2 diabetes patients, newly referred to or allocated for long-term follow-up in the out-patient clinic,
were mainly intermediate and high-risk, complicated patients (96 % and 95 %, respectively). Compliance of stratification
by endocrinologists was high. The concordance between endocrinologists’ and objective assessments was not strong.
Our data suggest that clinician-support for stratification level categorisation might be needed.
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Background
The global prevalence of type 2 diabetes (T2D) is in-
creasing [1–3]. The number of adults with diabetes was
estimated to be 382 million people in 2013 and rising to
592 million people in 2035 [2, 3]. T2D is a multifactorial
and chronic disease associated with serious complica-
tions and co-morbidities, and in 2014 it was ranked as
the 8th leading cause of deaths worldwide [4] and pre-
dicted to increase to the 7th ranking in 2030 [5]. Patients
with T2D have an increased morbidity and mortality
compared to the general population [6–8] due to an in-
creased risk of macrovascular disease as well as micro-
vascular complications such as nephropathy, retinopathy
and neuropathy. Studies have shown that the risk of
complications associated with T2D can be reduced or
delayed among patients with newly diagnosed T2D by
initiating and keeping tight glucose [9] and blood pres-
sure control [10]. In the Steno-2 study patients with
T2D and micro-albuminuria were offered an intensive
multifactorial intervention, and demonstrated significant
reductions in micro and macrovascular diseases at
13.3 years-follow-up compared to patients in conven-
tional therapy [11]. Thus, in order to prevent or delay
the onset of complications, it is essential to offer an
evidence-based and well-organised diabetes care.
Taking the growing number of patients with T2D into
account, it is relevant to target allocation of medical care
according to the need of the individual patient and the
existing resources [12]. In order to meet these circum-
stances the Danish National Board of Health integrated
elements of the Chronic Care Model [13, 14] and risk
stratification in a national strategy for treatment and
care of patients with chronic diseases in 2008 [15]. As a
consequence, the Capital Region of Denmark developed
a program for patients with T2D, recommending
patients with T2D to be stratified into three levels de-
pending on the severity and complications of their dis-
ease [16]. Stratification may be used to objectively assess
and target patients to treatment, care and specialty level
according to the severity of the disease and the patient's
ability to self-care.
Patients stratified to level 1 have well-controlled T2D
without clinically relevant complications, while patients at
level 2 and level 3 have less well controlled T2D and/or
increasing severity of complications and/or co-morbidity.
According to the model, patients stratified to level 3
should be followed in hospital-based outpatient clinics
where specialised and multidisciplinary treatment is avail-
able [16, 17]. Patients at level 1 are assumed to be allo-
cated to follow-up in general practice while patients at
level 2 are recommended intensified control by either the
general practitioner or the outpatient clinic, or ideally, in
cooperation between general practice and outpatient
clinic, preferably in a shared care follow-up [16].
The Danish risk stratification model may be a useful
tool in managing diabetes care for the growing number of
patients with T2D, as the model can offer guidance in the
distribution of both economic resources and the care bur-
den between general practitioners and outpatient clinics.
To what extent the Danish risk stratification model is used
in general practices or in hospitals, is currently unknown.
In our outpatient clinic local instructions recommend that
risk stratification takes place at the initial medical examin-
ation, at discharge from the diabetes clinic or at the transi-
tion to long-term follow-up, as well as once a year at the
annual extensive check-up.
The purpose of this study was to describe the patient
population according to stratification levels in a
hospital-based diabetes outpatient clinic and to investi-
gate the compliance of the endocrinologists to perform
stratification in accordance with an established risk
stratification model. Furthermore, we wanted to test the
concordance between the assessment performed by the
endocrinologists, and the objective assessment by the
established model available to the clinician.
Methods
We included patients with T2D followed in a hospital-
based diabetes outpatient clinic (Gentofte Hospital,
University of Copenhagen, Denmark). Patients in-
cluded in the trial were those followed in the clinic
during a period of 15 month (January 2013 until March
2014). Patients were identified from the electronic records
and were included if they had T2D and had an initial
medical examination (newly referred patients) or an an-
nual extensive check-up (long-term follow-up patients).
Patients
Patients attending the clinic were divided into either
newly referred or long-term follow-up patients. The newly
referred patients underwent initial medical examination
and attended medical visits during a period of approxi-
mately six months. After this initial period the patients
were either discharged to be followed by their general
practitioner or transferred to long-term follow-up in the
diabetes outpatient clinic based upon their level of stratifi-
cation. Patients in long-term follow-up were offered a
minimum of four visits a year; two control visits with an
endocrinologist, one with a trained diabetes nurse, and an
annual extensive check-up with an endocrinologist. Both
the initial examination and the annual extensive check-up
included blood and urine sampling, ECG, fundus photog-
raphy, as well as consultation with and risk stratification
by an endocrinologist. We included patients with T2D.
The patients were diagnosed with T2D before referral to
the outpatient clinic due to elevated HbA1c according to
international guidelines. Furthermore, all patients had
measurable C-peptide levels and/or long-term treatment
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with oral antidiabetic drugs. Patients with secondary dia-
betes and type 1 diabetes were excluded.
Data collection
The Danish risk stratification model stratifies patients
into three levels by their level of HbA1c, blood pressure,
and presence of albuminuria, as well as the presence of
micro- and macrovascular complications. The model is
designed as an organizational tool intending to graduate
specialised care and treatment according to the severity
and complexity of the disease. The model was originally
compiled by diabetes specialists and defined in a report
by the Capital Region of Denmark [16, 17]. The thresh-
olds and definitions characterising the three levels were
constructed by means of current evidence [16, 18–21].
In the present study, the model was slightly modified in
order to clarify the criteria and make the model more
operational, however not altering the overall model cri-
teria. The criteria for the different levels in the model
used are shown in Fig. 1. No formal clinical definition of
severe insulin resistance exists in the literature to our
knowledge. In our study, severe insulin resistance was
defined as an insulin requirement >2.0 U/kg/day. This
was based on a mean dose of insulin required for treat-
ment of normal weight younger people with type 1 dia-
betes (assumed to be insulin sensitive) of approximately
0.6 U/kg/day [22]. Severe insulin resistance was set to an
insulin sensitivity below 30 % of the mean normal level,
corresponding to an insulin dose above 2.0 U/kg/day.
All criteria have to be fulfilled to be allocated to level 1,
only one criteria have to be fulfilled to be allocated to
level 3. Patients not fulfilling criteria for level 1 or 3
were allocated to level 2.
Objective stratification was conducted by applying
the Danish risk stratification model to the collected
computerised data. Data were collected from medical
records, laboratory files and the Clinical System
Organizer/DiabetesRask. The latter being a specific
diabetes database containing all diabetes relevant data
regarding treatment and status of the individual pa-
tient. All data concerning the newly referred patients
were identified at the first initial visit and data con-
cerning the long-term follow-up patients were identi-
fied at the most recent annual extensive check-up. For
the long-term follow-up patients, the results of urine
and blood samples were identified at the most recent
visit at the outpatient clinic in the study period. Two
authors; Lene Munch (LM) and Michael E. Røder (MR)
conducted the objective stratification independently.
In case of disagreement between the objective assess-
ments, the results were re-examined by LM and MR in
order to reach consensus. The model used was identi-
cal to the one available to the endocrinologists in the
outpatient clinic. In case of missing data, patients were
stratified according to the data available. Among the
newly referred patients, 17 patients had missing data
according to the seven parameters in the risk stratifica-
tion model; in 11 patients one missing and in six
 Level 1 Level 2 Level 3 
HbA c (mmol/mol) <53 53-75 >75 
Blood pressure, 
systolic/diastolic 
(mm Hg) 
<130/80 130/80-160/90 >160/90 
Metabolic 
complications No 
Severe insulin 
resistancea
Very fluctuating plasma 
glucoseb or severe 
hypoglycaemia 
CVDd ECAMsuoiverpenOoN >1 MACE, symptomatic CVD or NYHA II-IV  
Diabetic foot 
disease No 
Peripheral neuropathyc
or artery diseased
Previous or existing 
ulcer or Charcot foot 
Retinopathy No or simplex retinopathy 
Progression of 
retinopathy 
Macula oedema or 
proliferative retinopathy 
Nephropathy No Micro-albuminuriae Macro-albuminuriaf 
Fig. 1 The Danish risk stratification model for patients with type 2 diabetes. All parameters in level 1 have to be fulfilled to be allocated to risk
stratification level 1. At risk stratification level 2 at least one parameter has to be fulfilled in level 2, and none in level 3. Patients at level 3 have to fulfil
at least one of the parameters in level 3 [16]. HbA1c, haemoglobin A1c; CVD, cardiovascular disease; MACE, major cardiovascular event; NYHA, the New
York Heart Association functional classification in patients with heart disease [38]. a Severe insulin resistance: Insulin dose > 2.0 U/kg/day. b Very
fluctuating plasma glucose: Daily plasma glucose values of >15 mmol/l or <5 mmol/l. c Peripheral neuropathy: Vibration perception threshold ≥25 mV
evaluated by a biothesiometer. d Peripheral artery disease: Ankle-brachial index <0.9 with or without symptomatic claudication. e Micro-albuminuria: >1
occasion of urine-albumin/creatinine ratio between 30 and 300 mg/g. f Macro-albuminuria:: Urine-albumin/creatinine ratio ≥300 mg/g or an estimated
glomerular filtration rate <60 ml/min
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patient two missing data parameters in the risk stratifi-
cation model. Among the long-term follow-up patients
20 had one missing data parameter.
We aimed to explore plausible reasons for disagreement
between the endocrinologists’ and the objective assess-
ments. In cases, where the objective stratification level was
higher than the assessment performed by the endocrinolo-
gist, the reason for higher assessment was registered
according to the seven parameters in the Danish risk strati-
fication model (Fig. 1). In cases, where the endocrinologist
was assessing the patient to a higher level than the object-
ive assessment, plausible reasons for the endocrinologist’s
assessment was estimated on the basis of variables con-
cerning co-morbidity, body mass index (BMI) >35 kg/m2
and vulnerability, or no known reason.
Reporting of data results was made in accordance to
the STROBE statement checklist.
Statistical methods
In the description of the population’s clinical characteris-
tics and disease status, both newly referred and long-
term follow-up patients were categorised into risk strati-
fication levels, as it was assessed by the objective
assessors. Data are presented as mean ± standard devi-
ation (SD) and frequency and percentages for ordinal
and nominal data. We wanted to investigate possible as-
sociations between the objective assessment and whether
or not the patients were risk stratified by the endocrin-
ologist. This was tested by conducting Chi-square tests.
To measure the concordance between the clinical and
objective assessments, we used Cohen's kappa [23]. As data
were ordinal we conducted a weighted kappa, which
accounted for the size of disagreement. The following de-
fined the strength of agreement for the kappa coefficient: 0
= poor, 0.01–0.20 = slight, 0.21–0.40 = fair, 0.41–0.60 =
moderate, 0.61–0.80 = substantial, and 0.81–1 = almost per-
fect [24]. Furthermore, we used McNemar’s test to test for
marginal homogeneity [25], and Bowker’s test to test for
symmetry above and below the main diagonal [26].
P values of less than 0.05 were considered significant.
Data were analysed using SAS Enterprise guide, version 5.2.
Ethics
The study was conducted in accordance with the princi-
ples of the Helsinki declaration. The Danish Data Pro-
tection Agency approved the study protocol, anonymity
of the participants, the protection of identity, privacy
and handling of the data (journal no. 2007-58-0015).
Availability of Supporting Data
The database set was available for all authors of the
study, and will be available for other non-commercial re-
searchers on request.
Results
A total of 946 patients were identified and 21 were ex-
cluded; one patient never had an appointment and was
referred to another clinic and 20 patients were referred
to our clinic in March 2014, but did not have any
appointments until after the study period.
Sample characteristics
The population in the outpatient diabetes clinic con-
sisted of 925 patients with T2D. Of these 664 (72 %)
were included in the study. Twenty-two percent of the
population in the clinic did not have an initial medical
examination or an annual extensive check-up performed
during the period (Fig. 2). Demographic and clinical
characteristics of the newly referred and the long-term
follow-up patients are presented in Table 1.
Compliance to risk stratification
In total 664 patients had an initial medical examination
or an annual extensive check-up and of these, 589
(89 %) patients were risk stratified. Among the newly re-
ferred patients 245 had an initial medical examination,
and 209 (85 %) of these patients were risk stratified by
endocrinologists. Of the 419 patients in long-term
follow-up, 380 (91 %) were risk stratified by an endo-
crinologist. For the newly referred patients there was no
difference in whether or not patients were risk stratified
by the endocrinologists compared to the levels of object-
ive assessments (p =NS) (Table 2). Among the long-
term follow-up patients there was a significant difference
in whether or not patients were risk stratified by the en-
docrinologists compared to the levels of objective assess-
ments, as more patients at level 1 (33 %), compared to
patients at level 2 (7 %) or 3 (10 %), were not risk strati-
fied by the endocrinologists (p < 0.001) (Table 2).
Concordance in risk stratification
The rates of concordance are illustrated in Table 3. Among
the newly referred patients there was a fair agreement be-
tween the assessments conducted by the endocrinologists
and the objective assessments (kappa 0.39). There was a
difference in the marginal distribution, as the endocrinolo-
gists categorised significantly less patients at level 3 com-
pared to the objective assessment (p < 0.0001) (Table 3).
Within the group of newly referred patients, there were
more cases of disagreement due to the objective assessment
being higher than the endocrinologists’ assessment (83 %)
compared to cases where the endocrinologist assessed
higher than the objective assessment (17 %) (p < 0.0001).
The two most frequent reasons for the objective as-
sessments being higher than the endocrinologists’ as-
sessments were when the values of HbA1c (N = 32
(49 %)) and blood pressure (N = 25 (38 %)) were not
taken into account by the endocrinologist. Due to few
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cases of the endocrinologists assessing higher than the
objective assessment, there were no patterns in the
reasons for these mismatches.
Among the patients in long-term follow-up, there was
agreement in approximately 2/3 of cases, corresponding
to a moderate concordance (kappa 0.45). The test for
marginal distribution found consistency in the propor-
tion of stratification levels between the endocrinologists’
and the objective assessments (p =NS) (Table 3). The
cases of disagreement were equally distributed above
(56 %) and below (44 %) the main diagonal (NS). The
two most frequent reasons for the objective assessment
being higher than the endocrinologist’s assessment were
when the values of nephropathy (N = 20 (31 %)) and
HbA1c (N = 16 (25 %)) were not taken into account by the
endocrinologist. The most frequent plausible reason for
endocrinologist assessing higher than the objective assess-
ment was the presence of co-morbidity (N = 35 (69 %)).
Discussion
In the present study we found that the vast majority of the
patients with T2D in a hospital-based diabetes outpatient
clinic were allocated to stratification level 2 or 3 (96 %),
and only 4 % were allocated to level 1. The compliance of
stratification performance by the endocrinologists was
quite high, with 9 out of 10 of patients attending the clinic
being risk stratified. Disagreement between the endocri-
nologists’ assessments and the objective assessments was
found in a number of cases, corresponding to the level of
concordance being evaluated as fair among the newly re-
ferred and moderate among patients in long-term follow-
up. The disagreements among the newly referred patients
Newly referred patients with 
T2D  
(n = 312) 
Long-term follow-up 
patients withT2D  
(n = 613) 
Not diagnosed with 
T2D (n = 21) 
Initial medical examination  
(n = 245) 
Population in diabetes out-patient clinic (n = 925)
Stratified by 
endocrinologist 
and objective 
assessment  
(n = 209) 
Newer showed up  
(n = 19) 
Only stratified 
by objective 
assessment  
(n = 36) 
Not diagnosed with 
T2D (n = 15) 
Annual extensive check-up  
(n = 419) 
Stratified by 
endocrinologist 
and objective 
assessment  
(n = 380) 
Newer showed up  
(n = 7) 
No annual extensive 
check-up  
 (n = 172) 
Only stratified 
by objective 
assessment  
(n = 39)
No initial medical 
examination  
(n = 27) 
Fig. 2 Disposition of study population. T2D, type 2 diabetes
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Table 1 Demographic and clinical characteristics of the newly referred and long-term follow-up patients according to objective stratification levels
Newly referred patients Long-term follow-up patients
Level 1 (n = 9) Level 2 (n = 125) Level 3 (n = 111) All (n = 245) Level 1 (n = 18) Level 2 (n = 236) Level 3 (n = 165) All (n = 419)
Age (years, range) 55.3 (42–62) 62.3 (23–89) 65.8 (23–93) 63.6 (23–93) 55.3 (28–68) 63.6 (19–89) 68.6 (38–93) 65.2 (19–93)
Male sex – no. (%) 3 (33.3) 82 (65.6) 71 (64.0) 156 (63.7) 9 (50) 160 (67.8) 113 (68.5) 282 (67.3)
BMI (kg/m2)a 30.3 ± 8.2 30.5 ± 6.2 29.6 ± 5.3 30.1 ± 6.1 28.0 ± 5.3 30.1 ± 5.6 30.5 ± 5.9 30.2 ± 5.7
Diabetes duration - years 3.9 ± 5.1 5.4 ± 5.8 7.9 ± 8.0 6.5 ± 7.0 6.2 ± 5.3 8.5 ± 6.0 11.5 ± 7.1 9.6 ± 6.6
SBP (mmHg) 120.6 ± 7.0 140.6 ± 15.8 142.3 ± 24.4 140.7 ± 19.8 114.8 ± 9.1 134.0 ± 13.8 136.7 ± 17.4 134.3 ± 15.7
DBP (mmHg) 70.9 ± 5.2 81.1 ± 9.5 80.0 ± 12.7 80.3 ± 11.1 72.3 ± 5.3 78.2 ± 8.7 76.8 ± 10.1 77.4 ± 9.2
HbA1c (%)
(mmol/mol)
6.3 ± 2.4 (45 ± 3) 7.1 ± 3.1 (54 ± 10) 8.5 ± 4.5 (69 ± 26) 7.7 ± 4.1 (61 ± 21) 6.1 ± 2.7 (43 ± 6) 6.8 ± 3.1 (51 ± 10) 7.6 ± 3.9 (60 ± 19) 7.1 ± 3.5 (54 ± 15)
TC (mmol/l) 4.8 ± 0.8 4.4 ± 1.0 4.3 ± 1.2 4.3 ± 1.1 4.2 ± 1.4 4.0 ± 0.8 4.1 ± 1.1 4.0 ± 0.9
LDL-C (mmol/l) 2.3 ± 0.7 2.2 ± 1.0 2.1 ± 0.9 2.2 ± 0.9 2.2 ± 1.1 1.8 ± 0.6 1.9 ± 1.0 1.8 ± 0.8
HDL-C(mmol/l) 1.7 ± 0.4 1.3 ± 0.5 1.2 ± 0.4 1.3 ± 0.5 1.4 ± 0.4 1.3 ± 0.4 1.3 ± 0.4 1.3 ± 0.4
TG (mmol/l) 1.9 ± 0.6 2.0 ± 1.2 2.3 ± 1.5 2.1 ± 1.3 1.2 ± 0.6 2.1 ± 1.2 2.2 ± 1.3 2.1 ± 1.2
Retinopathy – no. (%)
Any stage 0 3 (2.4) 6 (5.4) 9 (3.7) 0 20 (8.5) 35 (21.2) 55 (13.1)
Macular oedema or
proliferative retinopathy 0 0 3 (2.7) 3 (1.2) 0 0 4 (2.4) 4 (1.0)
Neuropathy – no. (%)
Peripheral neuropathy or insufficiency 0 60 (48.0) 58 (52.3) 118 (48.2) 0 128 (54.2) 111 (67.3) 139 (33.2)
Previous or existing ulcer or Charcot foot 0 0 8 (7.2) 8 (3.3) 0 0 13 (7.9) 13 (3.1)
Nephropathy – no. (%) 0 0 36 (32.4) 36 (14.7) 0 0 89 (53.9) 89 (21.2)
Former MACE – no. (%) 0 25 (20.0) 34 (30.6) 59 (24.1) 0 45 (19.1) 51 (30.9) 96 (22.9)
>1 MACE, symptomatic CVD
or NYHA II-IV – no. (%)
0 0 26 (23.4) 26 (10.6) 0 0 56 (33.9) 56 (13.4)
Mean ± standard deviation
BMI body mass index; SBP systolic blood pressure; DBP diastolic blood pressure; HbA1c haemoglobin A1c; TC total cholesterol; LDL low density lipoprotein; HDL high density lipoprotein; TG triglycerides; CVD
cardiovascular disease; MACE major cardiovascular event; NYHA the New York Heart Association functional classification in patients with heart disease [36]
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were primarily due to the objective assessments being
higher than the endocrinologists’. Among the patients in
long-term follow-up the mismatches were almost equally
distributed between the objective and the endocrinolo-
gists’ assessments.
The proportion of the three levels of risk stratification
is often represented as a pyramid shape in the context of
the chronic care model with most patients in level 1,
and fewest in level 3 [13, 27, 28]. A Dutch study testing
a disease management program for patients with dia-
betes (97 % with T2D) found a pyramid-shaped distribu-
tion of the patients at baseline (Low complexity: 54 %,
Medium complexity: 34 %, High complexity: 10 %) [28].
Their definitions of the three levels were however not
very detailed, but overall it seems comparable to the
model we used. The patients were recruited from both
general practitioners and an outpatient clinic, and the
group allocation was performed by a team, consisting of
the general practitioner, a diabetes nurse specialist and
an endocrinologist. However, after a 24-month follow-up
period the distribution of patients had changed to a
non-pyramid shape, as 66 % of the patients were
assigned to the medium complexity group (level 2),
while 23 % and 11 % were assigned to low (level 1) and
high (level 3) complexity, respectively [28]. The change
in the size of the groups was mainly due to changes in
HbA1c in the patients at level 1 at follow-up, which lead
to many patients being transferred from level 1 to level
2 [28]. The predominance of patients in level 2 were in
line with a Danish study [29], using a risk stratification
model similar to ours. They identified patients with dia-
betes, primarily T2D, followed by either a general practi-
tioner or at a specialised outpatient clinic, via medical
records from general practitioners. Sixty-two percent of
these patients were stratified to level 2, while level 1 and
3 accounted for 21 % and 15 %, respectively [29]. The
distribution of patients’ level of risk stratification was not
pyramid-shaped in our study, as the vast majority of pa-
tients were level 2 or 3 patients. This is in line with two
Asian studies stratifying ambulatory T2D patients, into
four risk levels, as 59 % [30] and 64 % [31] of the patients
were categorised into the high risk level (level 3). The
population distribution in our study is in accordance with
guideline recommendations allocating patients with a sub-
stantial degree of risk and disease complexity to specia-
lised hospital-based diabetes outpatient clinics, and
patients at risk level 1 should solely be managed by the
general practitioner [16]. Whether or not the population
distribution of risk stratification will appear as a pyramid
shape may depend on the criteria defining the three levels.
According to Kaiser-Permanente, who developed the
three-level risk stratification model, the threshold value
for HbA1c for level 2 was 10 % [13], while it was 7 % in
the risk stratification model used in our study and the
study by Qvist et al. [29].
One possible reason for the discrepancy between assess-
ments conducted by the endocrinologists and objective as-
sessments could be due to the model being insensitive to
other clinical factors adding to the complexity of the man-
agement of the disease and care of the patient with T2D.
The model could be more sensitive if relevant co-
Table 2 Possible associations between risk stratification levels
by objective assessment and whether or not patients were
stratified by the endocrinologist
Newly referred patients – n (%)
Objective assessment
Level 1 Level 2 Level 3
Assessment by endocrinologist No 0 (0) 19 (15) 17 (15)
Yes 9 (100) 106 (85) 94 (85)
Total 9 (100) 125 (100) 111 (100)
Chi-Square test: p = NS
Long-term follow-up patients – n (%)
Objective assessment
Level 1 Level 2 Level 3
Assessment by endocrinologist No 6 (33) 16 (7) 17 (10)
Yes 12 (67) 220 (93) 148 (90)
Total 18 (100) 236 (100) 165 (100)
Chi-Square test: p < 0.001
Table 3 Concordance of endocrinologists´ and objective
assessment of risk stratification in newly referred and in long-term
follow-up patients
Newly referred patients – n (%)
Objective assessment
Level 1 Level 2 Level 3 Total
Endocrinologists´
assessment
Level 1 9 (4.3) 18 (8.6) 7 (3.3) 34 (16.3)
Level 2 0 75 (36.9) 40 (19.1) 115 (55.0)
Level 3 0 13 (6.2) 47 (22.5) 60 (28.7)
Total 9 (4.3) 106 (50.7) 94 (45.0) 209 (100)
Observed agreement: 62.7 %, kappa = 0.39 (CI: 0.29–0.50), McNemar’s
test for marginal distribution: p < 0.0001, Bowker’s test for symmetry:
p < 0.0001
Long-term follow-up patients – n (%)
Objective assessment
Level 1 Level 2 Level 3 Total
Endocrinologists´
assessment
Level 1 7 (1.8) 12 (3.2) 1 (0.3) 20 (5.3)
Level 2 5 (1.3) 162 (42.6) 51 (13.4) 218 (57.4)
Level 3 0 46 (12.1) 96 (25.38) 142 (37.4)
Total 12 (3.2) 220 (57.9) 148 (38.9) 380 (100)
Observed agreement: 69.7 %, kappa = 0.45 (CI: 0.36–0.53), McNemar’s
test for marginal distribution: p = NS, Bowker’s test for symmetry: p = NS
CI confidence interval
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morbidities were incorporated into the model, as it was al-
legedly the most frequent reason for the endocrinologists
to allocate patients to a higher level compared to the ob-
jective assessment in the present study. Information on
major cardiovascular events (MACE), symptomatic cardio-
vascular disease and heart failure was integrated in our
model, but other clinical relevant co-morbidities could be
relevant as well. One study integrated co-morbidities as a
separate parameter in the model [17] and defined it as se-
vere co-morbidity requiring another disease-specific man-
agement than the endocrinologist [17]. This definition is
very broad as it will include co-morbidities not being rele-
vant to T2D, and thereby allocate patients to higher risk
levels. If co-morbidities are going to be incorporated in the
model, it must be defined in a clear and precise way.
Blood pressure was one of the most frequent reasons
for the objective assessment being higher than the endo-
crinologists, as endocrinologists tended to underestimate
the value of the blood pressure in the categorisation of
stratification level; therefore the thresholds for blood
pressure and the circumstances under which it was mea-
sured should be discussed. Blood pressure measured at
the doctor’s office, even after 5–10 min of rest, may still
be higher than the ‘real’ value, for instance due to white
coat hypertension. A recent review found that monitoring
24-h ambulatory blood pressures was a better predictor of
cardiovascular events than office blood pressure levels. In
terms of blood pressure control in patients with T2D, the
authors recommended a more frequent usage of 24-h am-
bulatory blood pressure monitoring [32]. Furthermore, the
Danish risk stratification model can be discussed as the
defined thresholds did not take individual treatment goals
into account. For instance, the glycaemic target is often
more stringent for patients with T2D only treated with
metformin and lifestyle changes and less stringent for pa-
tients with more advanced micro or macrovascular dis-
eases or extensive co-morbidities [20]. This indicates that
the model can be used as guidance in the risk stratification
performance, but the clinical assessment performed by the
endocrinologists will be conclusive for the actual risk level
allocation of the individual patient.
Even though the present study found discrepancies in
one third of the assessments, a modified version of the
model might be useful in identifying patients at risk. The
substantial number of disagreements might be reduced if
an electronic decision support system calculating an esti-
mated stratification level was available during the consult-
ation for the endocrinologist. Electronic support systems
for generating risk stratification levels have been devel-
oped and tested in ambulatory diabetes care [30, 33] as
well as in primary care clinics [34–36]. The Joined Asian
Decision Evaluation (JADE) program was validated by fol-
lowing a cohort, and after a median follow-up period of
5.5 years it was shown that higher risk levels were
associated with increased risk of clinical endpoints such as
CVD, end-stage renal disease and death [30]. In addition
to risk stratification, the JADE program produces a care
protocol with predefined management plans and sched-
ules for follow-up to support decision making and pro-
mote the interaction between the patient and the
healthcare professional [30, 33]. The program tested in
primary care clinics in USA is extended with suggestions
for regulation of treatment [34]. While the Asian model
[30, 33] incorporated multiple parameters for generating a
risk level for the patient, the American model [34] risk
stratified for each parameter. The latter is similar to the
diabetes-specific database already used in our clinic
Future research should investigate whether or not a risk
stratification model is a relevant and useful tool in the or-
ganisation of the growing number of patients with T2D.
The model used in the present study recommends that pa-
tients should be assigned to a speciality level in accordance
with increasing severity and complexity of the disease, and
personal abilities [16, 37]. The majority of patients in our
study seemed to be at medium or high risk levels where
emerging complications could progress if proper and
medium-level specialty care is not given [9, 11, 18, 19]. It
seems to be the case that some of these patients are cur-
rently controlled in primary care and some are controlled
at a specialised level [13]. Therefore, it would be relevant to
investigate if this group of patients, at the medium-risk
level, would benefit from a shared care follow-up, where
the general practitioners have the responsibility for the dia-
betes care and treatment and the regular visits at the gen-
eral practitioners office are combined with an annual
extensive check-up in a specialised diabetes outpatient
clinic. Such an intervention could offer highly specialised
diabetes care and at the same time diluting the care burden
between general practitioners and hospital-based outpatient
clinics.
To our knowledge, this is the first study investigating
the degree of agreement between clinical and objective
assessments by the use of a risk stratification model for
patients with T2D. Furthermore, the present study in-
cluded a large group of patients, who were unselected
and included consecutively. The objective assessments of
risk stratification levels were conducted according to a
well-defined model [16].
The present study had some limitations. Initially we
included all patients with T2D followed in the outpatient
clinic. However, some patients, especially those in the
long-term follow-up, did not have an annual extensive
check-up performed and had to be excluded from the
study since risk stratification was meant to be performed
at this visit according to our clinic visit schedule. This is
a bias in our study, as this group may represent a certain
type of patients; e.g. patients with irregular visiting pat-
terns at the clinic as well as instability regarding self-
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care. Reasons for the mismatches in risk stratification as-
sessments could also be that not all data were available
for the endocrinologist at the time of visit, for instance
test results from urine and blood samples taken the
same morning as the visit. However, this is considered
not to be influencing the overall results of the study, as
it rarely occurs. Another limitation is that this is a single
center study. Including patients from multiple diabetes
outpatient clinics could enhance the external validity of
the results.
Conclusions
In conclusion, the endocrinologists were generally com-
pliant in performing the risk stratification, and the popu-
lation allocated for long-term specialised follow-up was
indeed patients with medium or high risk and complex-
ity in accordance with guidelines Our data suggest an
opportunity for decision support to improve adherence
to the Danish risk stratification guidelines. It might offer
guidance for the organisation of future diabetes care in
general practice, specialised diabetes outpatient clinics
and improved cooperation between these caregivers.
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